Press Room

Clinical Cancer Research Publishes Study Demonstrating Clinically Meaningful and Statistically Significant Prognostic Improvement by the Breast Cancer IndexSM...
Clinical Cancer Research, the official journal of the American Association for Cancer Research, reported results of an…
Biotheranostics’ Chief Scientific Officer Nominated for Athena Pinnacle Award
Catherine Schnabel, Ph.D., recognized for supporting women in the San Diego Life Sciences Industry …
Biotheranostics Raises $32 Million in a Private Equity Financing & Announces Spinout From bioMérieux
Biotheranostics, a leader in molecular diagnostics for cancer, today announced that …
Studies Demonstrate Broadening Clinical Utility of Biotheranostics’ Breast Cancer Index Molecular Test in the Extended Endocrine Setting
Results Presented at San Antonio Breast Cancer Symposium Illustrate BCI’s Contribution to Advancing Clinical Care
Yale Study Shows Biotheranostics’ Breast Cancer Index MolecularSM Test Impacts Extended Endocrine Therapy Decisions in clinical practice
Clinical Use of Breast Cancer Index Led to Fewer Recommendations for Treatment & Reduced Patient Anxiety
Biotheranostics Announces Collaboration with DeNovo Sciences to Evaluate Its Proprietary Cancer Biomarkers for Use in Liquid Biopsies
Biotheranostics, Inc., a leader in molecular diagnostics for cancer, today announced a collaboration agreement with DeNovoSciences, Inc., …
Journal of the National Comprehensive Cancer Network Review Article Highlights Role of Biotheranostics’ Breast Cancer IndexSM in Optimizing Endocrine Therapy
Molecular test facilitates more personalized treatment, helping determine which patients with early stage, ER+ breast cancer are likely to benefit from extended endocrine therapy
ASCO Conference Data Show Biotheranostics’ Molecular Tests Significantly Impact Management of Metastatic Cancer Patients
Two Key Studies Support Role of CancerTYPE ID® Molecular Cancer Classifier & CancerTREATMENT NGS+ Biomarker Panels in Diagnosis & Management of Challenging Cancers
Studies Presented at 2015 ASCO Meeting Demonstrate Predictive Power of Biotheranostics’ Breast Cancer IndexSM Molecular Test in Endocrine Therapy Decisions
Ability to Predict Benefit from Extended Endocrine Therapy Impacts Treatment & Reduces Patient Anxiety
Study Underscores Value of Biotheranostics’ Breast Cancer IndexSM in Informing Decisions about Long-Term Endocrine Therapy & Assessing Risk of Late Recurrence
Miami Breast Cancer Conference Study & Workshop Reinforce Clinical Utility of Test Along the Continuum of Patient Care
Lifetime’s “The Balancing Act” Show for Women to Discuss the Breast Cancer IndexSM Molecular Test
Lifetime’s “The Balancing Act” Show for Women to Discuss the Breast …
Biotheranostics Appoints Key Executives to Leadership Team
FOR IMMEDIATE RELEASE…Jan. 9, 2015…SAN DIEGO…Biotheranostics, Inc., a leader in molecular …